Across TCGA pan-cancer cohorts, LCE2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LCE2A data layer compared with 11 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LCE2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCE2A expression acts as an unfavorable survival marker.

LUAD and LGG are the cancer types where LCE2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.178	0.684	.001	20	view →
LGG	OS	Median	All	0.268	0.801	<.001	7	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LCE2A tumor-vs-normal RNA expression · all LCE2A data types